Earnings summaries and quarterly performance for AADI.
Research analysts who have asked questions during AADI earnings calls.
JC
Joseph Catanzaro
Wolfe Research, LLC
3 questions for AADI
Also covers: CPRX, CRDF, CTMX +7 more
AD
Ahu Demir
Ladenburg
2 questions for AADI
AD
Ahu Demir
Ladenburg Thalmann
2 questions for AADI
Also covers: CYCC, IMCR, SLRX
Dan
HC Wainwright
1 question for AADI
Also covers: APDN, SNOW
GW
Greg Weasner
TD Cowen
1 question for AADI
Joe Catanzaro
Piper Sandler
1 question for AADI
Also covers: CNTB, CTMX, IMAB +1 more
Liang Cheng
Jefferies
1 question for AADI
Also covers: CTMX, INO, VXRT
RS
Roger Song
Jefferies
1 question for AADI
Also covers: AKBA, ALT, ALXO +13 more
Recent press releases and 8-K filings for AADI.
Whitehawk Provides Pipeline Update and 2026 Outlook
AADI
New Projects/Investments
Guidance Update
Product Launch
- Whitehawk was formed through the in-licensing of a three-asset ADC portfolio from Ushi Biologics, with its first programs going into the clinic in Q4 2025.
- The company plans to submit Investigational New Drug (IND) applications for its lead programs, HAWK-007 (PTK7-targeted ADC) and HAWK-016 (MUC16-targeted ADC), in Q4 2025, with clinical trials expected to start in Q1 2026.
- For its third asset, HAWK-206 (SEZ6-targeted ADC), Whitehawk plans to submit the IND in mid-2026 and commence the clinical trial in the second half of 2026.
- Whitehawk expects to present preclinical data for all three programs in the first half of 2026 and initial clinical data for HAWK-007 and HAWK-016 around Q1 2027.
- The company reported $163 million in cash at the start of Q4 2025, providing a cash runway through early 2028.
Dec 3, 2025, 5:30 PM
Whitehawk Therapeutics provides pipeline update and financial outlook
AADI
New Projects/Investments
Guidance Update
- Whitehawk Therapeutics, formed by in-licensing a three-asset ADC portfolio, is advancing its pipeline with HAWK-007 (PTK7-targeted) and HAWK-016 (MUC16-targeted) submitting Investigational New Drug (IND) applications in Q4 2025 and initiating clinical trials in Q1 2026.
- The third asset, HAWK-206 (SEZ6-targeted), is undergoing IND-enabling work, with IND submission anticipated in mid-2026 and clinical trial commencement in the second half of 2026.
- The company expects to present initial clinical data for all three programs around Q1 2027.
- Whitehawk reported $163 million in cash at the start of Q4 2025, providing a cash runway through early 2028.
Dec 3, 2025, 5:30 PM
Whitehawk Therapeutics Presents Differentiated ADC Platform and Clinical Pipeline
AADI
New Projects/Investments
Product Launch
Guidance Update
- Whitehawk Therapeutics is advancing a differentiated portfolio of next-generation antibody drug conjugates (ADCs) targeting PTK7, MUC16, and SEZ6 for a broad range of cancer indications.
- The company's ADC platform utilizes a novel topo-1 inhibitor payload and highly stable linker chemistry, which has demonstrated 5-25 times lower levels of free payload in plasma and a 2-3 times higher safety margin in non-clinical models compared to conventional topo-1-based ADCs.
- Whitehawk ended the past quarter with over $160 million in cash, providing a financial runway into 2028 and supporting anticipated key clinical data milestones for all three programs.
- The company is rapidly advancing its three assets into the clinic, with Investigational New Drug (IND) applications for HWK-007 (PTK7-targeted) and HWK-016 (MUC16-targeted) expected this quarter, and HWK-206 (SEZ6-targeted) to follow by mid-next year. Initial data readouts for HWK-007 and HWK-016 are anticipated in early 2027.
Nov 18, 2025, 11:30 AM
Whitehawk Therapeutics Provides Update on Next-Generation ADC Platform and Clinical Pipeline
AADI
New Projects/Investments
Product Launch
Guidance Update
- Whitehawk Therapeutics is advancing a portfolio of next-generation antibody drug conjugates (ADCs) targeting PTK7, MUC16, and SEZ6, leveraging an advanced platform with a novel topo-1 inhibitor payload and highly stable linker chemistry.
- The company's ADC platform shows significant advantages in pre-clinical measures, including 3-10 times higher tumor potency, 5-25 times lower free payload levels for improved stability, and a 2-3 times higher safety margin compared to conventional topo-1 ADCs.
- Whitehawk anticipates filing Investigational New Drug (IND) applications for HAWK-007 and HAWK-016 in Q4 2025, with HAWK-206 to follow by mid-2026. The earliest clinical data readouts for HAWK-007 and HAWK-016 are expected in early 2027.
- As of the end of the past quarter (Q3 2025), Whitehawk reported over $160 million in cash, providing a financial runway into 2028.
Nov 18, 2025, 11:30 AM
Whitehawk Therapeutics provides update on next-generation ADC platform and clinical pipeline
AADI
New Projects/Investments
Guidance Update
- Whitehawk Therapeutics is advancing a differentiated portfolio of next-generation antibody drug conjugates (ADCs) targeting PTK7, MUC16, and SEZ6, built on an advanced platform featuring a novel topo-1 inhibitor payload and highly stable linker chemistry.
- The company ended the past quarter with over $160 million in cash, providing a financial runway into 2028 and enabling anticipated key clinical data milestones for all three programs.
- Pre-clinical data indicates Whitehawk's platform offers significant advantages, including 3-10 times lower doses for tumor reduction, 5-25 times lower free payload levels in plasma, and a 2-3 times higher safety margin compared to typical topo-1-based ADCs.
- Investigational New Drug (IND) applications for lead assets HAWK-007 and HAWK-016 are expected this quarter (Q4 2025), with HAWK-206 to follow by mid-2026. Earliest clinical data readouts for HAWK-007 and HAWK-016 are projected for early 2027.
Nov 18, 2025, 11:30 AM
Aadi Bioscience, Inc. Completes Divestiture Transaction
AADI
M&A
- Completion of divestiture: The company completed the sale of 100% of its Aadi Subsidiary, Inc. shares in a transaction finalized on March 25, 2025, under a stock purchase agreement with involved parties including KAKEN INVESTMENTS INC. and KAKEN PHARMACEUTICAL CO., LTD.
- Significant cash proceeds: The deal resulted in a cash payment of $102.4 million to the company, following applicable purchase price adjustments.
- Upcoming financial disclosures: The company intends to file the pro forma financial information related to this divestiture within four business days following the transaction closure.
Mar 26, 2025, 12:00 AM
Aadi Bioscience Transitions to Whitehawk Therapeutics in Q4 2024
AADI
Earnings
New Projects/Investments
Debt Issuance
- Rebranding and strategic transactions: The company announced its transformation from Aadi Bioscience to Whitehawk Therapeutics, refocusing on advanced ADC therapies. This includes completing key transactions such as the divestiture of FYARRO to Kaken and securing $100 million in PIPE financing.
- Pipeline advancement: Whitehawk's portfolio now centers on three ADC candidates—HWK-007 targeting PTK7, HWK-016 aimed at MUC16, and HWK-206 focused on SEZ6—with plans to file U.S. INDs within the next 15 months.
- Financial update: For Q4 2024, the company reported $47.2 million in cash and cash equivalents, FYARRO net product sales of $7.2 million in the quarter (with full-year sales of $26 million), and a Q4 net loss of $18.3 million. The current cash position is expected to fund operations into 2028.
Mar 19, 2025, 12:31 PM
Aadi Bioscience Rebrands as Whitehawk Therapeutics
AADI
New Projects/Investments
M&A
- Name Change & Ticker Update: The company has rebranded from Aadi Bioscience, Inc. to Whitehawk Therapeutics, Inc., with its common stock set to trade under the ticker WHWK on Nasdaq starting March 19, 2025.
- Financial Highlights: For Q4 2024, the company reported $7.2 million in quarterly revenue and $26.0 million for the full year, with cash, cash equivalents, and short-term investments at $47.2 million as of December 31, 2024.
- Strategic ADC Focus: The firm is shifting its focus to accelerate a portfolio of advanced antibody drug conjugate (ADC) therapies, leveraging in-licensed assets and advanced technology platforms, with a robust balance sheet expected to support operations into 2028.
Mar 18, 2025, 12:00 AM
Aadi Bioscience announces strategic transformation, asset sale, and new ADC pipeline
AADI
M&A
New Projects/Investments
- Aadi Bioscience announced the approval of three transformative transactions, including the sale of FYARRO and associated infrastructure to KAKEN Pharmaceuticals for $100 million and a $100 million PIPE financing.
- The company is pivoting its strategy to focus on a new pipeline of Antibody Drug Conjugates (ADCs), having in-licensed three preclinical ADC programs from WuXi Biologics for an aggregate upfront payment of $44 million, with potential cumulative development and commercial milestones totaling up to $805 million.
- These transactions, combined with existing cash, are expected to provide Aadi with a cash runway into 2028.
- The new ADC pipeline includes assets targeting PTK7, MUC16, and SEZ6, with plans to file Investigational New Drug (IND) applications for PTK7 in H2 2025, MUC16 by end of 2025, and SEZ6 by mid-2026.
Mar 3, 2025, 2:50 PM
Whitehawk Therapeutics Completes Strategic Transformation with Asset Sale, ADC In-Licensing, and Financing
AADI
M&A
New Projects/Investments
Board Change
- Whitehawk Therapeutics received stockholder approval on February 28, 2025, for three transformative transactions.
- The company will sell Fiaro and its associated infrastructure to Kakin Pharmaceuticals for $100 million in cash.
- Whitehawk Therapeutics also entered an agreement to in-license three preclinical antibody drug conjugates (ADCs) from WuXi Biologics for an aggregate upfront payment of $44 million, with potential cumulative development milestones of up to $265 million and commercial milestones of up to $540 million.
- A private investment in public equity (PIPE) financing of $100 million was secured, with common stock sold at $2.40 per share.
- These transactions, combined with existing cash, are expected to provide Whitehawk Therapeutics with a cash runway into 2028.
Mar 3, 2025, 2:50 PM
Quarterly earnings call transcripts for AADI.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more